Should you buy Acrivon Therapeutics stock now?
No, the technical signal for Acrivon Therapeutics is currently SELL. Acrivon Therapeutics trades at $1.67 as of 8/6/2026. The overall technical signal is: Sell. The technical analysis shows the following: MACD is negative (bearish trend) at -0.052 with falling momentum (signal: -0.037); RSI is at 48.7 (neutral zone); the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $11.50 points to 590.7% upside. This is a technical observation based on current data, not investment advice.
What is the price target for Acrivon Therapeutics stock?
The average analyst price target for Acrivon Therapeutics is $11.50. The current price is $1.67, which gives an upside of 590.7%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $10.35 and $12.65.
Is Acrivon Therapeutics a dividend stock?
No, Acrivon Therapeutics does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Acrivon Therapeutics stock?
Acrivon Therapeutics is rated as a stock with extreme risk. the annual standard deviation is 93.5%, which classifies the stock as extreme risk.
Is Acrivon Therapeutics overvalued?
No, Acrivon Therapeutics is considered undervalued based on the analyst price target (590.7% upside). Acrivon Therapeutics has the following valuation ratios: a P/B ratio of 0.7. The analyst price target suggests that the stock is undervalued by 590.7%.
Is Acrivon Therapeutics overbought?
No, Acrivon Therapeutics is not overbought. RSI is at 48.7 (neutral zone). The technical indicators show: RSI is at 48.7 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 2.9% below the 20-day average (short-term downtrend). In addition, MACD is negative with falling momentum (bearish).
When is the next Acrivon Therapeutics earnings report?
Acrivon Therapeutics reports its next earnings on August 12, 2026. The stock currently trades at $1.67.
Is Acrivon Therapeutics shorted?
Yes, Acrivon Therapeutics is shorted with 5.2% of the free float sold short. This is a high level of short selling, which suggests some investors are betting on falling prices. Positive surprises can lead to a moderate short squeeze. Data is updated daily based on official filings with the SEC.
Are insiders buying Acrivon Therapeutics stock?
No, insiders are not buying Acrivon Therapeutics shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 7 sales. On a net basis, 30,485 $ worth of shares were sold. Across the last 20 reported transactions, the split is 4 purchases and 16 sales, with a net 7,009,534 $ bought. Active sellers include Miller Mary, Blume-Jensen Peter, Peterson Katharine and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Acrivon Therapeutics a good stock?
Based on our total score, Acrivon Therapeutics is rated as a disastrous stock with a total score of 16 out of 100. The stock scores very low on value, quality and momentum – it is among the worst in our database. The score is made up of Value: 27/100, Quality: 7/100, Momentum: 14/100. In addition: analysts see 590.7% upside to the price target; technical signal: Sell. Whether Acrivon Therapeutics is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Acrivon Therapeutics stock?
The outlook for Acrivon Therapeutics based on current data: the average analyst price target is $11.50 (+590.7%); the next earnings report is due on 8/12/2026, which can move the price. Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Acrivon Therapeutics stock falling?
Acrivon Therapeutics is falling right now. The technical indicators show: the price is 2.9% below the 20-day average; MACD is negative with falling momentum (bearish signal); short interest is 5.2% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Acrivon Therapeutics go?
The average analyst price target for Acrivon Therapeutics is $11.50, which corresponds to a potential gain of 590.7% from the current price of $1.67. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Acrivon Therapeutics fall?
We lack enough history to give a specific floor for Acrivon Therapeutics. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Acrivon Therapeutics do?
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acri... The company belongs to the Sundhed sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Acrivon Therapeutics as an investment.
Did Acrivon Therapeutics raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Acrivon Therapeutics. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Acrivon Therapeutics making money or losing money?
We have no current profitability data for Acrivon Therapeutics. See the latest report in the earnings history above.
Can Acrivon Therapeutics go bankrupt?
The bankruptcy risk of Acrivon Therapeutics is rated as elevated. Altman Z2 (a model for assessing financial distress) is -0.58 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 1 — which is weak. Debt relative to equity is 11% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Acrivon Therapeutics have a lot of debt?
No, Acrivon Therapeutics has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 11%. For the sundhed sector, anything below 80% counts as low debt. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
